MUMSS
OREX

Mitsubishi UFJ Morgan Stanley Securities’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Mitsubishi UFJ Morgan Stanley Securities’s Portfolio OREX Stock Details OREX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-780
Closed -$48K – 300
2013
Q3 		$48K Buy
+780
New +$52.8K 0.08% 74

Other funds holding OREX

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCA
SAC Capital Advisors Stamford, Connecticut $19.3B AUM 31.93% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Mitsubishi UFJ Morgan Stanley Securities's OREX Position: Q4 2013 in Review

Mitsubishi UFJ Morgan Stanley Securities sold out of Orexigen Therapeutics, Inc. (OREX) in Q4 2013, closing a stake of 780 shares — an estimated $48K sold.

Mitsubishi UFJ Morgan Stanley Securities first reported a position in OREX in Q3 2013 and held it in 1 quarter. The position peaked at $48K in Q3 2013. 124 funds tracked by Wall St. Rank hold OREX as of Q4 2013.

  • Mitsubishi UFJ Morgan Stanley Securities reported no remaining Orexigen Therapeutics, Inc. position as of Q4 2013 after selling out during the quarter.
  • Mitsubishi UFJ Morgan Stanley Securities sold 780 Orexigen Therapeutics, Inc. shares in Q4 2013, an estimated $48K.
  • Mitsubishi UFJ Morgan Stanley Securities first reported a position in Orexigen Therapeutics, Inc. in Q3 2013 and held it in 1 quarter.
  • Mitsubishi UFJ Morgan Stanley Securities's Orexigen Therapeutics, Inc. position peaked at $48K in Q3 2013.
  • 124 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q4 2013.

Based on Mitsubishi UFJ Morgan Stanley Securities's 13F filing for Q4 2013, filed 13 Feb 2014.